Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Netilmicin + dexamethasone is a fixed-dose ophthalmic combination of an aminoglycoside antibiotic (netilmicin) and a corticosteroid (dexamethasone). It is primarily used for the treatment of ocular inflammatory conditions where there is a risk or presence of superficial bacterial infection. Dexamethasone acts as a potent anti-inflammatory agent by inhibiting the release of arachidonic acid and subsequent production of pro-inflammatory mediators such as prostaglandins and leukotrienes. Netilmicin provides broad-spectrum antibacterial activity by inhibiting bacterial protein synthesis at the 30S ribosomal subunit, making it effective against various Gram-positive and Gram-negative bacteria, including methicillin-resistant strains. The combination has demonstrated efficacy in reducing signs and symptoms associated with conjunctival inflammation, postoperative ocular inflammation (such as after cataract surgery), and posterior blepharitis in moderate-severe dry eye patients[1][2][3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on netilmicin + dexamethasone.